Diabetes research and clinical practice最新文献

{"title":"Glycaemic remission in type 2 diabetes and subsequent microvascular and macrovascular outcomes: a systematic review and meta-analysis.","authors":"Chenglu Ruan, Xiang Zheng, Lin Wang","doi":"10.1016/j.diabres.2026.113600","DOIUrl":"https://doi.org/10.1016/j.diabres.2026.113600","url":null,"abstract":"<p><p>Type 2 diabetes remission may reduce the long-term burden of vascular complications, but the magnitude and consistency of this association remain uncertain. We systematically evaluated whether remission was associated with lower subsequent microvascular and macrovascular or cardiovascular risk compared with non-remission. PubMed/MEDLINE and Europe PMC were searched through 31 August 2026 for longitudinal cohorts comparing adults with and without biochemical remission. Eight reports from seven independent cohorts were included, with five cohorts contributing to quantitative vascular synthesis. Remission was associated with lower microvascular risk (pooled HR 0.68, 95% CI 0.59-0.77; I² = 4.1%) and lower macrovascular or cardiovascular risk (pooled HR 0.73, 95% CI 0.61-0.87; I² = 8.7%). Findings were consistent across lifestyle, routine-care, and metabolic-surgery settings. Additional cohorts associated remission with lower all-cause and cardiovascular mortality. However, risk of bias was moderate or serious because remission was not randomized and may reflect favorable post-baseline risk-factor changes. Type 2 diabetes remission is associated with substantially fewer subsequent vascular events, but causal attribution remains uncertain. Remission should complement, rather than replace, continued complication surveillance and multifactorial risk management.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"113600"},"PeriodicalIF":4.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149126772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospitalization outcomes in adults with type 2 diabetes mellitus treated with once-weekly insulin efsitora versus once-daily basal insulins: A post hoc analysis of the QWINT-1 to -4 randomized trials.","authors":"Athena Philis-Tsimikas, Rodolfo J Galindo, Bruno Guerci, Rebecca J Threlkeld, Bellina Mushala, C P Shyam, Andrea Goldyn","doi":"10.1016/j.diabres.2026.113586","DOIUrl":"https://doi.org/10.1016/j.diabres.2026.113586","url":null,"abstract":"<p><strong>Aims: </strong>To describe hospitalization and associated outcomes using pooled data from QWINT-1-4 trial participants.</p><p><strong>Methods: </strong>The multicenter, open-label, treat-to-target phase 3 QWINT-1 through QWINT-4 clinical trial program randomized adults with type 2 diabetes mellitus (T2D) toonce-weekly insulin efsitora alfa (efsitora)versus once-daily basal insulin comparators (insulin glargine: QWINT-1, QWINT-4; insulin degludec: QWINT-2, QWINT-3). This exploratory, post hoc analysis pooled data from QWINT-1-4 trials of participants receiving once-weekly efsitora(N = 1883) or once-daily basal insulin comparators (comparators, N = 1556). Unadjusted summary statistics by treatment group are reported for hospitalization incidence, duration of hospital stay, treatment discontinuation, glycated hemoglobin (HbA_1c), insulin doses, and hypoglycemia rates.</p><p><strong>Results: </strong>Overall, 173 (9.2 %) participants receiving once-weekly efsitora and 110 (7.1 %) receiving once-daily comparators (p = 0.17) were hospitalized. The duration of hospital stay was numerically similar for participants receiving efsitora (median 5.0 days) or comparators (median 5.0 days). Permanent treatment discontinuation, primarily driven by adverse events, was more frequent among efsitora-treated (26.6 %) than comparator-treated (16.4 %) participants (p = 0.03). Mean HbA_1c, insulin doses, and hypoglycemia rates before and after hospitalization were numerically similar in both groups.</p><p><strong>Conclusions: </strong>Once-weekly efsitora or once-daily insulin treatment does not appear to impact duration of hospitalization or glycemic parameters before or after hospitalization.</p><p><strong>Clinicaltrials: </strong>govidentifiers: NCT05662332 (QWINT-1), NCT05362058 (QWINT-2), NCT05275400 (QWINT-3), NCT05462756 (QWINT-4).</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"113586"},"PeriodicalIF":4.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149105581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of psychotherapy interventions on glycemic control and weight loss in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.","authors":"Rishita Rohilla, Rama Walia","doi":"10.1016/j.diabres.2026.113575","DOIUrl":"https://doi.org/10.1016/j.diabres.2026.113575","url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease which requires sustained lifestyle modifications. Psychological and diabetes-related distress may affect treatment adherence. Psychotherapy-based approaches are being incorporated into diabetes care, but their impact on glycemic control and anthropometric outcomes has not been clearly understood. We examined the effects of psychotherapy-based interventions on glycemic control (HbA_1c), body weight and body mass index (BMI) in adults with T2DM across fifty-two studies which were included in the analysis. Psychotherapy-based interventions showed a significant reduction in HbA_1c levels, with greatest effect at 3-month follow-up (MD - 0.53%, 95% CI - 0.80 to -0.25). Among anthropometric outcomes, weight loss was significantly reduced at 12 months (MD -3.58, 95% CI -5.62 to -1.53), whereas BMI showed less consistent effects. Overall, psychotherapy-based interventions resulted in consistent improvements in HbA_1c and longer-term reductions in body weight in adults with T2DM. The earlier improvements in HbA1c may reflect the influence of psychological support leading to changes in dietary and diabetes self-management behaviors, whereas anthropometric changes require sustained behavioral modification.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"113575"},"PeriodicalIF":4.6,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149007895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All-in-one sensor design with overlapping sensor transition reduces automode interruptions and improves patient-reported outcomes in adolescents with type 1 diabetes: real-world evidence from simplera sync integration.","authors":"Marco Marigliano, Andrea Scaramuzza, Riccardo Bonfanti, Valentino Cherubini, Fortunato Lombardo, Chiara Mameli, Nicola Minuto, Enza Mozzillo, Barbara Piccini, Elvira Piccinno, Ivana Rabbone, Carlo Ripoli, Riccardo Schiaffini, Davide Tinti, Claudio Maffeis","doi":"10.1016/j.diabres.2026.113570","DOIUrl":"10.1016/j.diabres.2026.113570","url":null,"abstract":"<p><strong>Aims: </strong>To assess the real-world impact of transitioning from Guardian 4 to Simplera Sync sensor on automated insulin delivery and patient-reported outcomes in adolescents using the Minimed 780G system.</p><p><strong>Methods: </strong>Multicentre retrospective observational study of 42 adolescents with type 1 diabetes (median age 12.0 years) established on SmartGuard ≥ 6 months. Fourteen centres each enrolled three consecutive eligible patients. Both observation windows fell within the school term, with no pump settings changed. Continuous glucose monitoring metrics and Diabetes Intrusiveness, Difficulty and Self-care Scale scores were compared between the final two weeks of Guardian 4 use and the final two weeks after transitioning to Simplera Sync.</p><p><strong>Results: </strong>Time in automated mode increased from 95.3% to 97.1% (+1.8 percentage points, approximately 23 min/day; p < 0.02). Time in range (70-180 mg/dL) increased from 76.7% to 79.3% (p < 0.05), mean glucose fell from 146.0 to 141.3 mg/dL (p < 0.05), and time above 250 mg/dL decreased from 3.0% to 2.0% (p < 0.01), with no worsening of hypoglycaemia. Treatment satisfaction increased and perceived burden decreased (both p < 0.01).</p><p><strong>Conclusions: </strong>Overlapping sensor transition was associated with increased automated delivery, modest glycaemic improvement and reduced device burden. The fully disposable design may eliminate transmitter-recharging interruptions; prospective validation is required.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"113570"},"PeriodicalIF":4.6,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148988434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint trajectories of periodontal disease and type 2 diabetes burden across 204 countries.","authors":"Chenglu Ruan, Huayuan Yang, Lin Wang","doi":"10.1016/j.diabres.2026.113569","DOIUrl":"10.1016/j.diabres.2026.113569","url":null,"abstract":"<p><strong>Objective: </strong>To test whether countries exhibit reproducible joint longitudinal patterns of periodontal disease and type 2 diabetes burden rather than a homogeneous global trajectory.</p><p><strong>Methods: </strong>This ecological study analysed age-standardised incidence, prevalence and disability-adjusted life-year rates for both conditions in 204 countries. Six annual trajectories were log-transformed, standardised and clustered using multivariate dynamic time warping with partitioning around medoids. Stability was assessed by 200 country-bootstrap replicates, an earlier observation window and principal-component k-means clustering.</p><p><strong>Results: </strong>Three ecological trajectory phenotypes were identified, comprising 19, 89 and 96 countries. They represented diabetes-dominant with periodontal decline, lower diabetes with intermediate periodontal burden, and high joint burden. The median bootstrap adjusted Rand index was 0.866; earlier-window and alternative-algorithm indices were 0.911 and 0.900, respectively. Shape-only clustering showed minimal agreement (0.010), indicating that burden magnitude materially defined the groups.</p><p><strong>Conclusions: </strong>National periodontal and type 2 diabetes burdens do not follow a single shared pattern. Reproducible ecological groupings may support integrated oral and metabolic health planning, but they neither demonstrate individual comorbidity nor establish a causal relationship.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"113569"},"PeriodicalIF":4.6,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consumer insights into low-energy formula diet interventions for type 2 diabetes management - A scoping review.","authors":"Qingzhou Liu, Sharon Breen, Mohan Men, Samantha Hocking","doi":"10.1016/j.diabres.2026.113559","DOIUrl":"10.1016/j.diabres.2026.113559","url":null,"abstract":"<p><p>Growing evidence indicates that early-stage type 2 diabetes is reversible. Remission may be achieved through substantial weight loss using low-energy and very-low-energy total diet replacement (LED and VLED TDR) interventions. Despite proven effectiveness, there is limited understanding of consumers' experiences and acceptability of such interventions. This scoping review aimed to provide an overview of the insights and experiences of consumers undertaking LED and VLED TDR interventions for type 2 diabetes management. A comprehensive literature search was conducted across five databases in accordance with PRISMA-ScR guidelines (from inception to February 2026). Fifteen studies were included. Overall, LED and VLED interventions were acceptable and formula diet products well tolerated. Key motivators for adherence during the intensive TDR phase included the potential for type 2 diabetes remission and weight loss. Broader benefits such as improvements in physical and psychological wellbeing were increasingly recognised as the interventions progressed. Identified challenges included inconsistent education delivery, insufficient psychological support, and limited consideration of cultural needs. Understanding of dietary quality and behaviour change beyond program completion remains limited, and small, homogenous samples may restrict the generalisability of findings. This highlights opportunities for tailored support in future programs to promote healthy lifestyle behaviours and optimise long-term remission outcomes.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"113559"},"PeriodicalIF":4.6,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International consensus recommendations for smoking cessation in type 2 diabetes from the DiaSmokeFree Working group.","authors":"Magdalena Walicka, Cristina Russo, Antonio Ceriello, Jacob George, Davide Campagna, Anoop Misra, Giusy Rita Maria La Rosa, Roberta Sammut, Riccardo Polosa","doi":"10.1016/j.diabres.2026.113528","DOIUrl":"https://doi.org/10.1016/j.diabres.2026.113528","url":null,"abstract":"<p><strong>Aims: </strong>To provide evidence-based recommendations for integrating smoking cessation into the prevention and management of type 2 diabetes (T2D).</p><p><strong>Methods: </strong>A multidisciplinary panel of 35 experts from 13 countries developed recommendations through a structured, multi-stakeholder consensus process, grading evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach where feasible, and reported findings in line with the Appraisal of Guidelines for Research and Evaluation (AGREE) framework.</p><p><strong>Results: </strong>Smoking remains common among people with T2D and is associated with increased cardiovascular, stroke, and macrovascular risk. Smoking cessation substantially reduces this risk. Evidence on pharmacological treatment in T2D is limited; varenicline is the only medication that can be strongly recommended. Intensive, individualized interventions combining pharmacotherapy, behavioral support, and relapse management are more effective than brief interventions, and drug-smoke interactions may require dose adjustments (e.g., for drugs affected by CYP1A2, UGT enzymes, or renal transporters).</p><p><strong>Conclusions: </strong>Adults with T2D who smoke require integrated, high-intensity cessation support throughout the quitting process to reduce diabetes-related complications and improve long-term health outcomes.</p>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":" ","pages":"113528"},"PeriodicalIF":4.6,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148849975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-like peptide-1 receptor agonists and hair loss: A systematic review and meta-analysis","authors":"Po-Lung Cheng ,&nbsp;Hua-Ching Chang","doi":"10.1016/j.diabres.2026.113333","DOIUrl":"10.1016/j.diabres.2026.113333","url":null,"abstract":"<div><h3>Aims</h3><div>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used drugs with applications beyond the management of obesity and diabetes mellitus. This study aimed to investigate the association between GLP-1 RA use and hair loss.</div></div><div><h3>Methods</h3><div>Four electronic databases were systematically searched for relevant studies published from inception to August 20, 2025. We included randomized controlled trials (RCTs) or prospective nonrandomized interventional studies that reported hair loss following GLP-1 RA therapy. A random-effects model was used for <em>meta</em>-analysis.</div></div><div><h3>Results</h3><div>A total of nine interventional studies, including 7 RCTs and 2 non-RCTs, were included in the final <em>meta</em>-analysis. Data from a total of 4114 GLP-1 RA users were analyzed. The pooled analysis revealed a significantly higher risk of hair loss in GLP-1 RA users than in placebo users (risk ratio [RR]: 3.252; 95% confidence interval [CI]: 1.437 to 7.358). The significant results persisted even when the analysis was restricted to RCTs focusing on patients with overweight or obesity (RR: 3.587; 95% CI: 2.100 to 6.124). Furthermore, a single-arm analysis revealed that the event rate of hair loss following GLP-1 RA therapy was 3.9%.</div></div><div><h3>Conclusions</h3><div>The use of GLP-1 RAs is significantly associated with an increased risk of hair loss.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"237 ","pages":"Article 113333"},"PeriodicalIF":7.4,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “One-hour plasma glucose concentration identify subjects at high risk for future type 2 diabetes based on β-cell function”. [Diabetes Res, Clin. Pract. 230 (2025) 112960]","authors":"Yahui Mu ,&nbsp;Qianwen Nie ,&nbsp;Xue Jin ,&nbsp;Aimei Dong","doi":"10.1016/j.diabres.2025.113060","DOIUrl":"10.1016/j.diabres.2025.113060","url":null,"abstract":"","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"233 ","pages":"Article 113060"},"PeriodicalIF":7.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147395234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vestibular dysfunction in people with diabetes is predicted by clinical measures of peripheral neuropathy and associated with imbalance and low physical activity","authors":"Frank E. DiLiberto ,&nbsp;Heather E.R. Kamath ,&nbsp;Maxine L. Olson ,&nbsp;Steven A. Miller ,&nbsp;Janet O. Helminski ,&nbsp;Marcello Cherchi ,&nbsp;Michael C. Schubert","doi":"10.1016/j.diabres.2026.113162","DOIUrl":"10.1016/j.diabres.2026.113162","url":null,"abstract":"<div><h3>Aims</h3><div>To characterize and predict otolith dysfunction of the peripheral vestibular system and its effect on balance in people with diabetes mellitus (DM).</div></div><div><h3>Methods</h3><div>This cross-sectional study included people with DM and peripheral neuropathy (PN), DM without PN, and controls (N = 68). Participant characteristics (e.g., age, HbA1c) including clinical measures of PN were procured. Cervical (saccule pathway) and ocular (utricle pathway) vestibular evoked myogenic potential (VEMP) testing outcomes included interamplitude and absent response counts. The Functional Gait Assessment and activity watch step counts characterized participant function. VEMP outcomes were compared between groups. In all DM participants, logistic regression was used to predict VEMP responses from participant characteristics, and functional outcomes were compared between those with and without VEMP responses.</div></div><div><h3>Results</h3><div>Worse PN predicted abnormal utricle and saccule function (1.1 ≤ odds ratio ≤ 1.7, <em>p</em> ≤ 0.05). Utricle function was the worst (<em>p</em> ≤ 0.04) and more frequently absent in those with DMPN. Balance and physical activity were worse in those with absent utricle (<em>p</em> ≤ 0.03), but not saccule, responses.</div></div><div><h3>Conclusions</h3><div>Clinical measures of PN can provide rationale for vestibular testing as those with DM and abnormal utricle function have imbalance and low physical activity.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"233 ","pages":"Article 113162"},"PeriodicalIF":7.4,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146212366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}